Nautilus Historical Balance Sheet

NAUT Stock

USD 0.91 0.03 3.54%

Trend analysis of Nautilus Biotechnology balance sheet accounts such as Total Current Liabilities of 5.2 M provides information on Nautilus Biotechnology's total assets, liabilities, and equity, which is the actual value of Nautilus Biotechnology to its prevalent stockholders. By breaking down trends over time using Nautilus Biotechnology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Nautilus Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nautilus Biotechnology is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

About Nautilus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Nautilus Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Nautilus Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Nautilus Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Nautilus currently owns. An asset can also be divided into two categories, current and non-current.

Nautilus Biotechnology Balance Sheet Chart

At this time, Nautilus Biotechnology's Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 1.3 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 180.1 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Nautilus Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nautilus Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Nautilus Biotechnology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nautilus Biotechnology are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Nautilus Biotechnology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Nautilus Biotechnology current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.At this time, Nautilus Biotechnology's Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 1.3 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 180.1 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	30.3M	34.6M	30.5M	46.9M
Total Assets	350.1M	305.6M	242.7M	243.0M

Short Long Term Debt Total Total Assets

Nautilus Biotechnology balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Currrent Assets Other	Other Assets	Property Plant Equipment	Warrants
Total Assets		-0.28	0.72	0.78	0.93	-0.71	-0.62	0.79	0.18	-0.46	-0.27	0.81	-0.46	-0.4	0.46	0.88	-0.47	0.87	0.84	0.86	0.87	0.9	0.7	0.82	0.36	-0.22
Short Long Term Debt Total	-0.28		0.05	0.04	0.05	0.79	-0.07	-0.02	-0.62	-0.46	-0.11	0.01	-0.46	0.92	0.46	0.02	-0.65	0.04	0.06	0.04	0.02	0.02	-0.02	0.04	-0.06	-0.06
Other Current Liab	0.72	0.05		0.97	0.83	-0.27	-0.86	0.49	-0.23	-0.79	0.05	0.92	-0.79	0.03	0.79	0.91	-0.72	0.8	0.92	0.87	0.94	0.91	0.88	0.88	0.7	-0.37
Total Current Liabilities	0.78	0.04	0.97		0.89	-0.33	-0.89	0.58	-0.19	-0.83	0.05	0.98	-0.83	0.03	0.83	0.96	-0.77	0.84	0.97	0.92	0.98	0.93	0.93	0.93	0.75	-0.4
Total Stockholder Equity	0.93	0.05	0.83	0.89		-0.46	-0.74	0.81	-0.09	-0.71	-0.23	0.91	-0.71	-0.07	0.71	0.96	-0.76	0.94	0.94	0.94	0.95	0.96	0.8	0.91	0.46	-0.29
Net Debt	-0.71	0.79	-0.27	-0.33	-0.46		0.16	-0.62	-0.31	0.0	-0.11	-0.36	0.0	0.72	0.0	-0.4	-0.17	-0.52	-0.35	-0.38	-0.4	-0.45	-0.43	-0.34	-0.29	0.0
Retained Earnings	-0.62	-0.07	-0.86	-0.89	-0.74	0.16		-0.31	0.11	0.74	0.09	-0.89	0.74	0.02	-0.74	-0.86	0.72	-0.65	-0.88	-0.91	-0.88	-0.77	-0.82	-0.94	-0.67	0.75
Cash	0.79	-0.02	0.49	0.58	0.81	-0.62	-0.31		-0.28	-0.57	0.05	0.59	-0.57	0.0	0.57	0.67	-0.53	0.9	0.64	0.65	0.66	0.75	0.65	0.58	0.39	0.0
Non Current Assets Total	0.18	-0.62	-0.23	-0.19	-0.09	-0.31	0.11	-0.28		0.65	-0.56	-0.08	0.65	-0.81	-0.65	-0.06	0.53	-0.33	-0.12	-0.11	-0.12	-0.18	-0.37	-0.08	-0.45	0.11
Cash And Short Term Investments	-0.46	-0.46	-0.79	-0.83	-0.71	0.0	0.74	-0.57	0.65		-0.29	-0.78	1.0	-0.52	-1.0	-0.75	0.92	-0.77	-0.78	-0.75	-0.79	-0.76	-0.88	-0.76	-0.79	0.4
Common Stock Total Equity	-0.27	-0.11	0.05	0.05	-0.23	-0.11	0.09	0.05	-0.56	-0.29		-0.05	-0.29	0.29	0.29	-0.17	0.08	0.02	-0.13	-0.19	-0.09	-0.08	0.33	-0.17	0.66	0.09
Common Stock Shares Outstanding	0.81	0.01	0.92	0.98	0.91	-0.36	-0.89	0.59	-0.08	-0.78	-0.05		-0.78	-0.04	0.78	0.98	-0.75	0.82	0.98	0.94	0.98	0.91	0.89	0.95	0.69	-0.41
Short Term Investments	-0.46	-0.46	-0.79	-0.83	-0.71	0.0	0.74	-0.57	0.65	1.0	-0.29	-0.78		-0.52	-1.0	-0.75	0.92	-0.77	-0.78	-0.75	-0.79	-0.76	-0.88	-0.76	-0.79	0.4
Non Current Liabilities Total	-0.4	0.92	0.03	0.03	-0.07	0.72	0.02	0.0	-0.81	-0.52	0.29	-0.04	-0.52		0.52	-0.08	-0.56	0.02	-0.03	-0.08	-0.05	-0.05	0.07	-0.08	0.17	0.05
Other Current Assets	0.46	0.46	0.79	0.83	0.71	0.0	-0.74	0.57	-0.65	-1.0	0.29	0.78	-1.0	0.52		0.75	-0.92	0.77	0.78	0.75	0.79	0.76	0.88	0.76	0.79	-0.4
Other Stockholder Equity	0.88	0.02	0.91	0.96	0.96	-0.4	-0.86	0.67	-0.06	-0.75	-0.17	0.98	-0.75	-0.08	0.75		-0.76	0.88	1.0	0.97	0.99	0.94	0.85	0.96	0.58	-0.39
Total Liab	-0.47	-0.65	-0.72	-0.77	-0.76	-0.17	0.72	-0.53	0.53	0.92	0.08	-0.75	0.92	-0.56	-0.92	-0.76		-0.72	-0.79	-0.77	-0.77	-0.74	-0.7	-0.76	-0.5	0.38
Total Current Assets	0.87	0.04	0.8	0.84	0.94	-0.52	-0.65	0.9	-0.33	-0.77	0.02	0.82	-0.77	0.02	0.77	0.88	-0.72		0.86	0.88	0.89	0.95	0.86	0.83	0.57	-0.27
Common Stock	0.84	0.06	0.92	0.97	0.94	-0.35	-0.88	0.64	-0.12	-0.78	-0.13	0.98	-0.78	-0.03	0.78	1.0	-0.79	0.86		0.96	0.99	0.93	0.87	0.96	0.61	-0.41
Net Tangible Assets	0.86	0.04	0.87	0.92	0.94	-0.38	-0.91	0.65	-0.11	-0.75	-0.19	0.94	-0.75	-0.08	0.75	0.97	-0.77	0.88	0.96		0.97	0.93	0.86	0.99	0.57	-0.58
Property Plant And Equipment Net	0.87	0.02	0.94	0.98	0.95	-0.4	-0.88	0.66	-0.12	-0.79	-0.09	0.98	-0.79	-0.05	0.79	0.99	-0.77	0.89	0.99	0.97		0.96	0.9	0.97	0.65	-0.42
Accounts Payable	0.9	0.02	0.91	0.93	0.96	-0.45	-0.77	0.75	-0.18	-0.76	-0.08	0.91	-0.76	-0.05	0.76	0.94	-0.74	0.95	0.93	0.93	0.96		0.87	0.91	0.58	-0.33
Non Currrent Assets Other	0.7	-0.02	0.88	0.93	0.8	-0.43	-0.82	0.65	-0.37	-0.88	0.33	0.89	-0.88	0.07	0.88	0.85	-0.7	0.86	0.87	0.86	0.9	0.87		0.86	0.9	-0.46
Other Assets	0.82	0.04	0.88	0.93	0.91	-0.34	-0.94	0.58	-0.08	-0.76	-0.17	0.95	-0.76	-0.08	0.76	0.96	-0.76	0.83	0.96	0.99	0.97	0.91	0.86		0.61	-0.62
Property Plant Equipment	0.36	-0.06	0.7	0.75	0.46	-0.29	-0.67	0.39	-0.45	-0.79	0.66	0.69	-0.79	0.17	0.79	0.58	-0.5	0.57	0.61	0.57	0.65	0.58	0.9	0.61		-0.39
Warrants	-0.22	-0.06	-0.37	-0.4	-0.29	0.0	0.75	0.0	0.11	0.4	0.09	-0.41	0.4	0.05	-0.4	-0.39	0.38	-0.27	-0.41	-0.58	-0.42	-0.33	-0.46	-0.62	-0.39

Click cells to compare fundamentals

Nautilus Biotechnology Account Relationship Matchups

Nautilus Biotechnology balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	85.0M	398.5M	350.1M	305.6M	242.7M	243.0M
Short Long Term Debt Total	4.8M	30.0M	30.3M	34.6M	30.5M	46.9M
Other Current Liab	1.1M	2.1M	1.5M	3.9M	2.5M	1.8M
Total Current Liabilities	3.0M	5.8M	6.8M	9.1M	7.6M	5.2M
Total Stockholder Equity	(29.7M)	363.6M	314.9M	265.4M	208.7M	180.1M
Net Debt	(31.8M)	(155.6M)	(84.2M)	15.2M	2.8M	2.8M
Retained Earnings	(30.3M)	(80.6M)	(138.6M)	(202.2M)	(273.0M)	(259.4M)
Cash	36.6M	185.6M	114.5M	19.4M	27.6M	26.3M
Non Current Assets Total	7.4M	49.2M	162.8M	128.7M	109.9M	94.9M
Cash And Short Term Investments	76.7M	345.7M	184.5M	173.4M	129.9M	123.4M
Common Stock Shares Outstanding	30.0M	84.5M	124.6M	124.9M	125.4M	79.2M
Short Term Investments	40.1M	160.1M	69.9M	154.0M	102.2M	97.1M
Liabilities And Stockholders Equity	85.0M	398.5M	350.1M	305.6M	242.7M	243.0M
Non Current Liabilities Total	111.7M	29.1M	28.3M	31.1M	26.4M	25.1M
Other Current Assets	303.8K	7.0M	2.7M	3.4M	2.9M	3.1M
Other Stockholder Equity	600K	444.4M	455.3M	467.8M	481.7M	291.4M
Total Liab	114.7M	34.9M	35.1M	40.2M	34.0M	45.7M
Total Current Assets	77.7M	349.2M	187.2M	176.8M	132.8M	148.0M
Property Plant And Equipment Net	6.2M	31.9M	32.6M	36.9M	32.3M	25.8M
Accounts Payable	470K	1.7M	1.3M	1.6M	987K	1.2M
Non Currrent Assets Other	527K	997K	1.1M	1.2M	1.4M	1.4M
Accumulated Other Comprehensive Income	3K	(184K)	(1.9M)	(255K)	57K	59.9K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nautilus Historical Balance Sheet

About Nautilus Balance Sheet Analysis

Nautilus Biotechnology Balance Sheet Chart

Total Assets

Total Current Liabilities

Nautilus Biotechnology balance sheet Correlations

Nautilus Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nautilus Biotechnology balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Nautilus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Investments	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Other Stockholder Equity
Property Plant And Equipment Net	+ 0.99	Other Stockholder Equity
Property Plant And Equipment Net	+ 0.99	Common Stock
Other Assets	+ 0.99	Net Tangible Assets
Common Stock Shares Outstanding	+ 0.98	Total Current Liabilities

Other Current Assets	- 1.0	Short Term Investments
Other Current Assets	- 1.0	Cash And Short Term Investments
Other Assets	- 0.94	Retained Earnings
Total Liab	- 0.92	Other Current Assets
Net Tangible Assets	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings